Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moderna Inc expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday.
https://finance.yahoo.com/news/1-moderna-expects-price-covid-223318215.html
Moderna says it compensated US more than enough for Covid-19 shot partnership
On Wednesday, Moderna chief executive Stephane Bancel will testify before a Senate panel about the price the company will charge for its vaccine after the US government stops buying the shots, shifting that responsibility to the private market.
https://www.straitstimes.com/world/united-states/moderna-paid-the-us-more-than-enough-for-covid-shot-partnership-executive-says
$MRNA
Moderna also has a personalized cancer vaccine (PCV) candidate in phase 2 trials that it's developing with Merck. As of February 2023, the FDA granted that program a Breakthrough Therapy Designation, too, which means that it could experience compressed development timelines. If it starts to report promising late-stage data, that should provide yet another shot in the arm for mrna
shares.
money for all ....maybe
Commonwealth's research also estimated that the U.S. vaccination program saved the country $1.15 trillion "in medical costs that would otherwise have been incurred."
Next week, Moderna CEO Stéphane Bancel will testify before the Senate Health, Education, Labor, and Pensions Committee on the price of his company's COVID-19 vaccine.
He'll face an unfriendly audience. Committee Chairman Sen. Bernie Sanders, I-Vt., claims that companies like Moderna profited off COVID at Americans' expense. He's eager to "rein in the greed of these pharmaceutical pandemic profiteers."
stay tuned>>>>>>>>>>
https://www.forbes.com/sites/sallypipes/2023/03/16/bernie-doesnt-get-healthcare-innovation/?sh=1b1e7031696e
These vaccine candidates for respiratory syncytial virus (RSV), cytomegalovirus (CMV), and flu are in phase 3 trials. So they're approaching the finish line. In fact, Moderna aims to file for regulatory approval of the RSV candidate by the end of the first half of this year.
$MRNA
our partner: Keytruda Unlocked: How Should Merck Proceed with Trials-
https://www.biospace.com/article/keytruda-unlocked-how-should-merck-proceed-with-keytruda-trials-/
About mRNA-4157/V940
Personalized cancer vaccines are designed to prime the immune system so that a patient can generate a tailored antitumor response specific to their tumor mutation signature. mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the patient's tumor. Upon administration into the body, the algorithmically derived and mRNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity.
mRNA-4157/V940 is being developed in combination with KEYTRUDA. mRNA-4157/V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. KEYTRUDA is an immunotherapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells.
Moderna and Merck plan to initiate a Phase 3 study in adjuvant melanoma in 2023 and expect to rapidly expand to additional tumor types, including non-small cell lung cancer.
The two abstract titles are:
Presentation #CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open- label Phase 2 mRNA-4157-P201/Keynote-942 trial. Harnessing the Immune System in the Clinic.
Session: Clinical Trials Plenary; Sunday, April 16 at 1:00-3:00 PM ET.
Presenter: Dr. Jeffrey S. Weber
Poster Session #CT224: Evaluation of minimal residual disease as a predictive biomarker of recurrence free survival in high-risk melanoma patients treated with a combination of mRNA-4157, a personalized cancer vaccine, and pembrolizumab.
Session: Phase II Clinical Trials 2; Tuesday, April 18 at 9:00 AM - 12:30 PM ET.
Author: Dr. Ryan J. Sullivan
stay tuned....
$MRNA
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL. mRNA-4157/V940 is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Phase-2-Data-on-mRNA-4157V940-an-Investigational-mRNA-Personalized-Cancer-Vaccine-to-be-Presented-at-the-2023-AACR-Annual-Meeting/default.aspx
It is prepared with veal or lamb.
Raw materials matter in mRNA vaccine and therapeutic development
https://www.fiercebiotech.com/sponsored/raw-materials-matter-mrna-vaccine-and-therapeutic-development
Study your lesson next time:
https://www.modernatx.com/research/product-pipeline
just search......Follow our instructions and you're done.
2 Top Biotech Stocks to Buy In March and Hold Forever:
$MRNA it has four programs in phase 3 clinical trials, and nine programs in phase 2 trials
Maravai LifeSciences is a biotech that's upstream of Moderna. It sells the nucleic acids that Moderna and other mRNA drug developers like BioNTech and Pfizer need to do research, conduct clinical trials, and manufacture doses of their mRNA medicines. That means if its customers are going to go big on their mRNA pipelines over the next decade, Maravai stands to make a ton of money along the way whether its customers succeed in commercializing new drugs or not.
very nice$
https://www.fool.com/investing/2023/03/13/2-biotech-stocks-to-buy-in-march-and-hold-forever/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Moderna may seek the FDA’s accelerated approval for its personalized cancer vaccine, the company’s president, Stephen Hoge, said Monday at Cowen’s 43rd Annual Healthcare Conference in Boston.
https://www.biospace.com/article/moderna-eyes-accelerated-approval-for-mrna-cancer-vaccine/
Moderna eyes human testing of mpox, bird flu vaccines this year: ‘They’re really for public health’
https://finance.yahoo.com/news/moderna-eyes-human-testing-mpox-180343041.html
Accelerated approval incoming? Moderna 'hopeful' for personalized cancer vaccine......
https://endpts.com/accelerated-approval-incoming-moderna-hopeful-for-personalized-cancer-vaccine/
(nice)------- stay tuned------
Reason to buy: It has oodles of cash to invest in long-term growth
For a biotech, there's nothing better than having a lot of money to spend on stuff like pioneering new pipeline programs, doing more preclinical research, and building additional platform capabilities. Biotech is a risky business, and the more money a company has, the more chances it has to hit a home run -- and the more times it can safely strike out without endangering its future.
On that note, Moderna ended 2022 with a mind-boggling $18.2 billion in cash, equivalents, and investments, and it plans to spend only $4.5 billion on research and development (R&D) in 2023. That means it could continue to spend like wild even if its earnings were to somehow drop to zero, which they won't.
It also means that the company will be able to easily acquire any promising upstarts that management thinks will be useful, not to mention opening the door to direct investments in key suppliers like Maravai LifeSciences if the need arises.
And that's why having a lot of cash is yet another reason to invest.
Reason to sell: Revenue is going to keep crashing for a while
https://www.fool.com/investing/2023/03/06/2-reasons-to-buy-moderna-stock-1-reason-to-sell/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
we are here to make money$$$$$$$$$
I don't care what you write
NOVAX
$MRNA
we are coming $MRNA
(BLA) for mRNA-1345 to the FDA in the first half of 2023
FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks
https://www.nbcdfw.com/news/business/money-report/fda-advisors-recommend-pfizer-rsv-vaccine-for-older-adults-despite-possible-guillain-barre-risks/3204213/
Four Aces!
relax$
LOL
Moderna, on its back foot, reassures investors on flu vaccine after mixed phase 3 data
https://www.fiercebiotech.com/biotech/moderna-dinged-lukewarm-flu-data-waits-efficacy-readout-charting-regulatory-course
After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique
https://www.nytimes.com/2023/02/23/science/moderna-covid-vaccine-patent-nih.html
Moderna reported quarterly earnings of $3.61 per share
The figure fell short of the $4.68 a share Wall Street expected
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61
Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12
Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key markets
https://investors.modernatx.com/news/news-details/2023/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2022-Financial-Results-and-Provides-Business-Updates/default.aspx
huge news cancer...
today: MODERNA TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 23, 2023
let's see what happens!
OK man $MRNA winner!
fake news!
Health Canada Authorizes MRNA Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
https://investors.modernatx.com/news/news-details/2023/Health-Canada-Authorizes-Modernas-Omicron-Targeting-Bivalent-COVID-19-Vaccine-in-Children--Adolescents-6-17-Years/default.aspx
Moderna said it has already updated mRNA-1010 in a way it believes will improve immune responses against Influenza B and will test those changes.
The first per protocol interim analysis of efficacy is now expected to be reviewed by an independent Data and Safety Monitoring Board (DSMB) before the end of the first quarter. Based on these results the DSMB will notify the Company whether the primary efficacy endpoint has been met or whether the study should continue accruing further cases towards the final analysis.
That’s the beauty of live
relax$
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards :let's see what happens
The Zacks Consensus Estimate and our model estimate for fourth-quarter product sales stand at $5.02 billion and $4.82 billion, respectively.
https://finance.yahoo.com/news/moderna-mrna-report-q4-earnings-151003349.html
relax: "Today's results represent an important step forward in the development of mRNA-based influenza vaccines to address the substantial burden of disease caused by influenza. We are encouraged by the safety and tolerability profile, and by the strong immunogenicity results against Influenza A viruses which cause the overwhelming majority of flu-related disease in older adults. We now look forward to the efficacy results from the ongoing pivotal Phase 3 efficacy study being conducted in parallel," said Stephen Hoge, M.D., Moderna's President. "While we did not achieve non-inferiority for the Influenza B strains which are more frequent in younger populations, we have already updated the vaccine that we believe could improve immune responses against Influenza B and will seek to quickly confirm those improvements in an upcoming clinical study thanks to the agility of our mRNA platform."
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Interim-Phase-3-Safety-and-Immunogenicity-Results-for-mRNA-1010-a-Seasonal-Influenza-Vaccine-Candidate/default.aspx
Moderna will keep its COVID vaccine on the market at no cost to consumers, even after the federal government stops paying for it, the company announced Wednesday.
"Everyone in the United States will have access to Moderna's COVID-19 vaccine regardless of their ability to pay," the company said in a statement.
Last month, the vaccine maker was slammed for reportedly considering a dramatic price increase for the shot, which it had developed with the help of the federal government.
https://abcnews.go.com/Health/moderna-covid-vaccine-remain-free-consumers-uninsured/story?id=97226324
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
https://finance.yahoo.com/news/u-backs-moderna-says-government-170221948.html
Fossil evidence reveals that cancer in humans goes back 1.7 million years
https://theconversation.com/fossil-evidence-reveals-that-cancer-in-humans-goes-back-1-7-million-years-63430
Cancer vaccines are already a reality—but your doctor might not tell you about them unless you ask
https://finance.yahoo.com/news/cancer-vaccines-already-reality-doctor-110000530.html
$MRNA
Let it go and it won't ever happen.